Urologix Competitors

Urologix (OTCMKTS:ULGX) and SpectraScience (OTCMKTS:SCIE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Analyst Ratings

This is a breakdown of current ratings and target prices for Urologix and SpectraScience, as provided by MarketBeat.com.

Earnings & Valuation

This table compares Urologix and SpectraScience's gross revenue, earnings per share (EPS) and valuation.

Volatility & Risk

Urologix has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500. Comparatively, SpectraScience has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.

Profitability

This table compares Urologix and SpectraScience's net margins, return on equity and return on assets.

Summary

Urologix beats SpectraScience on 1 of the 1 factors compared between the two stocks.

Urologix (OTCMKTS:ULGX) and Echo Therapeutics (OTCMKTS:ECTE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Analyst Ratings

This is a breakdown of current ratings and target prices for Urologix and Echo Therapeutics, as provided by MarketBeat.com.

Volatility & Risk

Urologix has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500. Comparatively, Echo Therapeutics has a beta of 7.09, indicating that its stock price is 609% more volatile than the S&P 500.

Earnings & Valuation

This table compares Urologix and Echo Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Urologix and Echo Therapeutics' net margins, return on equity and return on assets.

Summary

Echo Therapeutics beats Urologix on 1 of the 1 factors compared between the two stocks.

Urologix (OTCMKTS:ULGX) and Aksys (OTCMKTS:AKSY) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Urologix and Aksys' net margins, return on equity and return on assets.

Volatility and Risk

Urologix has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500. Comparatively, Aksys has a beta of -6.76, indicating that its stock price is 776% less volatile than the S&P 500.

Valuation & Earnings

This table compares Urologix and Aksys' gross revenue, earnings per share and valuation.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Urologix and Aksys, as provided by MarketBeat.com.

Summary

Urologix beats Aksys on 1 of the 1 factors compared between the two stocks.

Urologix (OTCMKTS:ULGX) and Escalon Medical (OTCMKTS:ESMC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Valuation and Earnings

This table compares Urologix and Escalon Medical's revenue, earnings per share and valuation.

Urologix has higher earnings, but lower revenue than Escalon Medical.

Volatility & Risk

Urologix has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Comparatively, Escalon Medical has a beta of -0.86, indicating that its share price is 186% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Urologix and Escalon Medical, as provided by MarketBeat.

Profitability

This table compares Urologix and Escalon Medical's net margins, return on equity and return on assets.

Summary

Urologix beats Escalon Medical on 4 of the 5 factors compared between the two stocks.

Heart Tronics (OTCMKTS:HRTT) and Urologix (OTCMKTS:ULGX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.

Volatility & Risk

Heart Tronics has a beta of 1024.78, indicating that its share price is 102,378% more volatile than the S&P 500. Comparatively, Urologix has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Heart Tronics and Urologix, as reported by MarketBeat.com.

Profitability

This table compares Heart Tronics and Urologix's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Heart Tronics and Urologix's revenue, earnings per share (EPS) and valuation.

Summary

Heart Tronics beats Urologix on 1 of the 1 factors compared between the two stocks.

Urologix (OTCMKTS:ULGX) and Ivivi Technologies (OTCMKTS:IVVI) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and target prices for Urologix and Ivivi Technologies, as reported by MarketBeat.com.

Profitability

This table compares Urologix and Ivivi Technologies' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Urologix and Ivivi Technologies' top-line revenue, earnings per share and valuation.